has spent 32 years in industrial drug discovery (7 at Burroughs-Wellcemo and 25 at GlaxoSmithkline). He received a Ph.D. in Pharmacology at the University of Alberta, Canada. He then joined Burroughs-Wellcome as an associate Scientist. From there he continued working in drug discovery at Glaxo Inc.,GlaxoWellcome and finally GlaxoSmithKline. Leaving his position as a Director at GlaxoSmithKline Research and Development laboratories at Research Triangle Park, N.C. USA, Dr. Kenakin is now a professor in the Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill. Currently he is engaged in studies aimed at the optimal design of drug activity assays systems, the discovery and testing of allosteric molecules for therapeutic application and the quantitative modeling of drug effects. In addition, he is Director of the Pharmacology curriculum at the UNC School of Medicine. He is a member of numerous editorial boards as well as Editor-in-Chief of the Journal of Receptors and Signal Transduction and Co-editor-in-Chief of Current Opinion in Pharmacology. He has authored numerous articles and has written 10 books on Pharmacology.
His interests include receptor pharmacology, drug discovery, and drug development. He has been an instructor with the American Chemical Society since 2003.